Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations
We characterized the effect of systemic therapy given after portal vein embolization (PVE) and before hepatectomy on hepatic tumor and functional liver remnant (FLR) volumes. All 76 patients who underwent right PVE from 2002–2016 were retrospectively studied. Etiologies included colorectal cancer (n...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
MDPI AG
2017
|
| Online Access: | http://hdl.handle.net/1721.1/109898 |
| _version_ | 1811094808683347968 |
|---|---|
| author | Deipolyi, Amy Zhang, Yu Naidu, Sailendra Borad, Mitesh Sahin, Burcu Mathur, Amit Oklu, Rahmi Khademhosseini, Alireza |
| author2 | Harvard University--MIT Division of Health Sciences and Technology |
| author_facet | Harvard University--MIT Division of Health Sciences and Technology Deipolyi, Amy Zhang, Yu Naidu, Sailendra Borad, Mitesh Sahin, Burcu Mathur, Amit Oklu, Rahmi Khademhosseini, Alireza |
| author_sort | Deipolyi, Amy |
| collection | MIT |
| description | We characterized the effect of systemic therapy given after portal vein embolization (PVE) and before hepatectomy on hepatic tumor and functional liver remnant (FLR) volumes. All 76 patients who underwent right PVE from 2002–2016 were retrospectively studied. Etiologies included colorectal cancer (n = 44), hepatocellular carcinoma (n = 17), cholangiocarcinoma (n = 10), and other metastases (n = 5). Imaging before and after PVE was assessed. Chart review revealed systemic therapy administration, SNaPshot genetic profiling, and comorbidities. Nine patients received systemic therapy; 67 did not. Tumor volume increased 28% in patients who did not receive and decreased −24% in patients who did receive systemic therapy (p = 0.026), with no difference in FLR growth (28% vs. 34%; p = 0.645). Among 30 patients with genetic profiling, 15 were wild type and 15 had mutations. Mutations were an independent predictor of tumor growth (p = 0.049), but did not impact FLR growth (32% vs. 28%; p = 0.93). Neither cirrhosis, hepatic steatosis, nor diabetes impacted changes in tumor or FLR volume (p > 0.20). Systemic therapy administered after PVE before hepatic lobectomy had no effect on FLR growth; however, it was associated with decreasing tumor volumes. Continuing systemic therapy until hepatectomy may be warranted, particularly in patients with genetic mutations. |
| first_indexed | 2024-09-23T16:05:28Z |
| format | Article |
| id | mit-1721.1/109898 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T16:05:28Z |
| publishDate | 2017 |
| publisher | MDPI AG |
| record_format | dspace |
| spelling | mit-1721.1/1098982022-09-29T18:10:30Z Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations Deipolyi, Amy Zhang, Yu Naidu, Sailendra Borad, Mitesh Sahin, Burcu Mathur, Amit Oklu, Rahmi Khademhosseini, Alireza Harvard University--MIT Division of Health Sciences and Technology Khademhosseini, Alireza We characterized the effect of systemic therapy given after portal vein embolization (PVE) and before hepatectomy on hepatic tumor and functional liver remnant (FLR) volumes. All 76 patients who underwent right PVE from 2002–2016 were retrospectively studied. Etiologies included colorectal cancer (n = 44), hepatocellular carcinoma (n = 17), cholangiocarcinoma (n = 10), and other metastases (n = 5). Imaging before and after PVE was assessed. Chart review revealed systemic therapy administration, SNaPshot genetic profiling, and comorbidities. Nine patients received systemic therapy; 67 did not. Tumor volume increased 28% in patients who did not receive and decreased −24% in patients who did receive systemic therapy (p = 0.026), with no difference in FLR growth (28% vs. 34%; p = 0.645). Among 30 patients with genetic profiling, 15 were wild type and 15 had mutations. Mutations were an independent predictor of tumor growth (p = 0.049), but did not impact FLR growth (32% vs. 28%; p = 0.93). Neither cirrhosis, hepatic steatosis, nor diabetes impacted changes in tumor or FLR volume (p > 0.20). Systemic therapy administered after PVE before hepatic lobectomy had no effect on FLR growth; however, it was associated with decreasing tumor volumes. Continuing systemic therapy until hepatectomy may be warranted, particularly in patients with genetic mutations. 2017-06-15T18:11:14Z 2017-06-15T18:11:14Z 2017-03 2017-02 Article http://purl.org/eprint/type/JournalArticle 2077-0383 http://hdl.handle.net/1721.1/109898 Deipolyi, Amy; Zhang, Yu; Khademhosseini, Ali; Naidu, Sailendra; Borad, Mitesh; Sahin, Burcu; Mathur, Amit and Oklu, Rahmi. “Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations.” Journal of Clinical Medicine 6, no. 3 (March 2017): 26 © 2017 The Authors en_US http://dx.doi.org/10.3390/jcm6030026 Journal of Clinical Medicine Creative Commons Attribution 4.0 International License http://creativecommons.org/licenses/by/4.0/ application/pdf MDPI AG MDPI |
| spellingShingle | Deipolyi, Amy Zhang, Yu Naidu, Sailendra Borad, Mitesh Sahin, Burcu Mathur, Amit Oklu, Rahmi Khademhosseini, Alireza Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations |
| title | Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations |
| title_full | Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations |
| title_fullStr | Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations |
| title_full_unstemmed | Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations |
| title_short | Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations |
| title_sort | portal vein embolization impact of chemotherapy and genetic mutations |
| url | http://hdl.handle.net/1721.1/109898 |
| work_keys_str_mv | AT deipolyiamy portalveinembolizationimpactofchemotherapyandgeneticmutations AT zhangyu portalveinembolizationimpactofchemotherapyandgeneticmutations AT naidusailendra portalveinembolizationimpactofchemotherapyandgeneticmutations AT boradmitesh portalveinembolizationimpactofchemotherapyandgeneticmutations AT sahinburcu portalveinembolizationimpactofchemotherapyandgeneticmutations AT mathuramit portalveinembolizationimpactofchemotherapyandgeneticmutations AT oklurahmi portalveinembolizationimpactofchemotherapyandgeneticmutations AT khademhosseinialireza portalveinembolizationimpactofchemotherapyandgeneticmutations |